Published in J Exp Med on August 29, 1997
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22
Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A (1999) 2.19
Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell (2011) 1.89
Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med (2009) 1.78
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest (2003) 1.70
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest (2007) 1.63
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol (2000) 1.47
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med (2000) 1.31
Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28
Nanoparticle delivery systems in cancer vaccines. Pharm Res (2010) 1.20
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer (2002) 1.14
Specificity in cancer immunotherapy. Semin Immunol (2008) 1.11
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J Immunol (2002) 1.08
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med (1999) 1.08
Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol (2002) 1.07
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood (2008) 0.99
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology (2006) 0.97
Intratumoral immunotherapy: using the tumour against itself. Immunology (2005) 0.97
Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A (2000) 0.96
Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol (1999) 0.96
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology (2012) 0.92
In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest (1998) 0.89
An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses. Oncotarget (2015) 0.89
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PLoS One (2011) 0.88
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother (2010) 0.88
Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol (2001) 0.86
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res (2014) 0.85
Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol (2013) 0.85
Retracted Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther (2012) 0.83
Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother (2013) 0.82
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate (2011) 0.81
Chemoenzymatic synthesis of mono- and di-fluorinated Thomsen-Friedenreich (T) antigens and their sialylated derivatives. Org Biomol Chem (2012) 0.79
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother (2014) 0.79
CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses. Clin Exp Immunol (2006) 0.79
An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS One (2015) 0.78
Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett (2015) 0.78
Allogeneic beta-islet cells correct diabetes and resist immune rejection. Proc Natl Acad Sci U S A (2002) 0.78
Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer (2000) 0.77
Stimulation of autoimmunity by toll-like receptor ligands. Ann Rheum Dis (2005) 0.75
Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant. PLoS One (2014) 0.75
Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget (2016) 0.75
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 5.30
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT. J Natl Cancer Inst (1964) 3.36
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature (1987) 2.90
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today (1997) 2.89
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity (1994) 2.56
Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst (1974) 2.47
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (1995) 2.01
Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A (1977) 1.85
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
The role of tyrosinase in autoimmune vitiligo. Lancet (1994) 1.66
Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc Natl Acad Sci U S A (1978) 1.63
Induction of anti-self-immunity to cure cancer. Cell (1995) 1.54
Limited capacity for tolerization of CD4+ T cells specific for a pancreatic beta cell neo-antigen. Immunity (1995) 1.52
Antibodies to normal human melanocytes in vitiligo. J Exp Med (1983) 1.50
The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection. Eur J Immunol (1987) 1.46
Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev (1995) 1.38
Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J (1993) 1.34
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol (1995) 1.30
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med (1996) 1.13
T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev (1995) 1.13
Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol (1994) 1.12
Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc Natl Acad Sci U S A (1994) 1.09
T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev (1991) 1.08
An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med (1993) 1.04
Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J Clin Invest (1996) 1.04
Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol (1994) 0.99
Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol (1994) 0.87
Functional analysis of the retinoblastoma gene product and of RB-SV40 T antigen complexes. Cancer Surv (1992) 0.87
Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev (1995) 0.85
Studies on transformation of Escherichia coli with plasmids. J Mol Biol (1983) 116.81
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
Plasmid screening at high colony density. Gene (1980) 16.47
MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol (1979) 15.58
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 13.24
Immune response in mice that lack the interferon-gamma receptor. Science (1993) 12.15
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants. Proc Natl Acad Sci U S A (1990) 10.46
Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell (1993) 9.84
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J Exp Med (1978) 9.51
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity. Transplant Rev (1976) 8.10
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature (1974) 6.99
Differential T cell costimulatory requirements in CD28-deficient mice. Science (1993) 6.93
Genetic and physical linkage of exogenous sequences in transformed cells. Cell (1980) 6.67
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev (1999) 6.10
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science (2000) 5.84
A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (2000) 5.78
McrA and McrB restriction phenotypes of some E. coli strains and implications for gene cloning. Nucleic Acids Res (1988) 5.76
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 5.27
Plasmid screening at high colony density. Methods Enzymol (1983) 5.24
Evidence for a differential avidity model of T cell selection in the thymus. Cell (1994) 5.24
Plasmid transformation of Escherichia coli and other bacteria. Methods Enzymol (1991) 5.21
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet (2001) 4.96
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 4.73
T-cell-mediated immunopathology in viral infections. Transplant Rev (1974) 4.72
T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity (2001) 4.62
Genes required for cytotoxicity against virus-infected target cells in K and D regions of H-2 complex. Nature (1975) 4.41
Isolation of the chicken thymidine kinase gene by plasmid rescue. Nature (1980) 4.37
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. J Exp Med (1978) 4.27
Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science (1997) 4.23
Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci U S A (1988) 4.19
Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol (1995) 4.16
H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med (1975) 4.16
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 4.08
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
ICOS is essential for effective T-helper-cell responses. Nature (2001) 4.01
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99
Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell (2001) 3.80
Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature (1998) 3.78
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991) 3.78
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Characteristics of an SV40-plasmid recombinant and its movement into and out of the genome of a murine cell. Cell (1980) 3.66
Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol (1998) 3.52
Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature (1975) 3.49
A biological role for the major histocompatibility antigens. Lancet (1975) 3.40
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J Exp Med (1996) 3.26
Construction and characterization of a 2.5-kilobase procollagen clone. Proc Natl Acad Sci U S A (1978) 3.26
On immunological memory. Annu Rev Immunol (1996) 3.21
A crucial role for B cells in neuroinvasive scrapie. Nature (1998) 3.19
Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clin Exp Immunol (2005) 3.12
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell (1993) 3.07
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer (2006) 3.05
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med (1997) 3.03
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Hybrid insulin genes reveal a developmental lineage for pancreatic endocrine cells and imply a relationship with neurons. Cell (1988) 2.99
Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev (1995) 2.97
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 2.96
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature (1987) 2.90
Neutralizing antiviral B cell responses. Annu Rev Immunol (1997) 2.86
Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science (1994) 2.86
Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. Nature (1985) 2.84
BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity (2000) 2.79
Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol (1994) 2.73
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood (1997) 2.71
Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur J Immunol (1989) 2.71
H-2 restriction of cell-mediated immunity to an intracellular bacterium: effector T cells are specific for Listeria antigen in association with H-21 region-coded self-markers. J Exp Med (1977) 2.71
Gene technology and democracy. Science (1997) 2.68
Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature (1991) 2.66
Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med (1990) 2.58